BeOne Medicines (BEIGF) Shares Outstanding (2015 - 2026)

BeOne Medicines (BEIGF) has reported Shares Outstanding (Entity) for 12 consecutive years, with $113.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 2.88% year-over-year to $113.0 million in Q2 2026; TTM through Jun 2026 was $113.0 million, a 2.88% increase from a year earlier, with the FY2025 full-year figure at $110.9 million, up 3.87% from the prior year.
• Shares Outstanding (Entity) was $113.0 million for Q2 2026 at BeOne Medicines, up from $111.1 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $113.0 million in Q2 2026 and troughed at $102.7 million in Q1 2022.
• A 5-year average of $106.7 million and a median of $106.0 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) climbed 12.04% in 2022 and slipped 0.23% in 2024, its largest moves.
• Over 5 years, Shares Outstanding (Entity) stood at $104.3 million in 2022, then grew by 0.25% to $104.6 million in 2023, then gained by 2.05% to $106.7 million in 2024, then climbed by 3.87% to $110.9 million in 2025, then climbed by 1.96% to $113.0 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $113.0 million (Q2 2026), $111.1 million (Q1 2026), and $110.9 million (Q4 2025), per Business Quant data.